The NaviMed team has over 40 years of collective healthcare experience in investing, operating, and clinical activities, complementary backgrounds, past experiences working together, and a depth of high-level strategic relationships in industry and with key health policy-makers.
Mr. Schwarz has nearly 20 years of investment and financing experience in healthcare. Prior to co-founding NaviMed Capital, Mr. Schwarz led the US healthcare venture and growth capital practice at The Carlyle Group for 14 years.
His team’s investing activities focused particularly on medical devices and products, healthcare information technology and selected healthcare services. He joined The Carlyle Group in 1997 at the inception of its $210 million initial US venture capital fund, and led the healthcare investing practice from that time through the venture group’s second fund, which closed on $602 million in 2001 targeting venture and growth capital investments, and third fund, which closed on $605 million in 2006 targeting growth capital investments and growth-oriented leveraged buyouts.
Mr. Schwarz previously was a Vice President in the healthcare group at Robertson Stephens, where he led the firm’s healthcare IT investment banking efforts and also served clients in the medical device and healthcare services sectors. Earlier in his career, Mr. Schwarz was an investment banker at Morgan Stanley.
Mr. Schwarz is currently a member of the Board of Directors of AcuFocus, AqueSys, NeoVista, and Proteus Digital Health. He was formerly a Director of numerous prior portfolio companies of The Carlyle Group, including Carefx (sold to Harris), ConnectiCare (sold to Emblem Health), Endius (sold to Zimmer), Fairchild Imaging (sold to BAE Systems), LipoSonix (sold to Medicis Pharmaceuticals) and Heritage Health Systems (sold to Universal American).
Mr. Schwarz currently serves on the Board of George Mason Intellectual Properties (GMIP) which manages the commercialization of the university’s patents. He also serves as President of the Hungarian-American Enterprise Scholarship Fund, which provides fellowships to promising young Hungarian nationals to obtain private sector professional experience in the United States. From 2006 to 2011, Mr. Schwarz served on the Board of the Mid-Atlantic Venture Association, the industry association for venture capital and private equity firms in the Mid-Atlantic region.
Mr. Schwarz holds an A.B. from Duke University where he was an Angier B. Duke Scholar, an M.B.A. from Harvard Business School, and a J.D. from Harvard Law School.
Bijan Salehizadeh, M.D.
Dr. Salehizadeh has 13 years of healthcare operating and investment experience. Prior to co-founding NaviMed Capital, he was a General Partner at Highland Capital Partners, where he focused on venture and growth stage healthcare investments.
Prior to joining Highland in 2003, Dr. Salehizadeh spent several years in marketing at Medtronic. Before Medtronic, Dr. Salehizadeh held a variety of senior management roles with HealthCentral, a venture-backed healthcare information technology company that went public in 1999. During his medical training, Dr. Salehizadeh conducted research in minimally invasive heart valves and left ventricular assist devices.
He is currently on the board of directors of Auris Surgical and Hyperion Therapeutics (IPO) and has sourced or been actively involved in Highland’s investments in AVEO Oncology (IPO), Baronova, BÂRRX Medical (sold to Covidien), Conor Medsystems (IPO; sold to Johnson & Johnson), Entourage Medical, kyruus, and Pharmaca Integrative Pharmacy.
Dr. Salehizadeh holds an A.B. in Molecular Biology from Princeton University, an M.D. and Master’s in Science in Health Policy from Columbia University, and an M.B.A. from Harvard Business School. He is also a graduate of the Kauffman Fellows Program.
Mr. Canann has 15 years of operating and investing experience with healthcare companies. Prior to co-founding NaviMed Capital, he focused on growth and venture stage healthcare investments at The Carlyle Group between 2004 and 2011.
Previously, he led the global marketing effort for the Endeavor drug-eluting stent development program at Medtronic, the world’s largest medical technology company. In this role, he successfully managed all aspects of the global launch plan, from clinical trial requirements and publication planning to regulatory and reimbursement activities across multiple geographies, required to achieve the company’s sales targets in this new $5 billion product category.
Prior to joining Medtronic, Mr. Canann held various strategic planning and global product management positions in the critical care division of Edwards Lifesciences (formerly Baxter International), the global leader in heart valves and hemodynamic monitoring. His responsibilities focused primarily on global product management for central venous catheters, introducers and Swan-Ganz catheters. Early in his career, Mr. Canann was a CPA in the Boston office of Price Waterhouse.
Mr. Canann currently serves on the Board of Directors of Elenza and previously served on the Board of Directors of several portfolio companies of The Carlyle Group including Carefx (sold to Harris Corporation) and Primary Health (sold to PacificSource Health Plans). In addition, he has been actively involved in Carlyle’s investments in Endius (sold to Zimmer), AqueSys and PixelOptics.
Since 2008, Mr. Canann has served on the Cleveland Clinic Innovation Advisory Board, a select group of healthcare investors and seasoned entrepreneurs who advise the Cleveland Clinic on the commercial viability, investment decisions and funding strategies for new technologies and services and provide feedback on business plans.
Mr. Canann holds an M.S. and a B.S. from Brigham Young University and an M.B.A. from Harvard Business School.
Mr. Chan has 7 years of healthcare experience. Prior to joining NaviMed Capital, Mr. Chan was part of the healthcare investment team at Siemens Venture Capital. Based out of Boston and Beijing, he evaluated and sourced healthcare deals worldwide, performed research on various market sectors and supported portfolio companies.
Mr. Chan also held an investment role at SAC Capital and a marketing role at Medtronic Cardiovascular. Mr. Chan started his career developing a molecular diagnostic technology at a venture backed company.
While at Siemens Venture Capital, Mr. Chan was a Board Observer at MD Datacor (sold to Noridian Mutual Insurance) and actively involved in the following investments: China Diagnostics, BioImagene (sold to Roche), RadPharm (sold to JLL Partners), U-Systems (sold to GE) and Cylex (assets sold to Viracor-IBT). Mr. Chan was a founding fellow of the Startup Leadership Program in 2007 and has mentored various start-ups to raise over $30 million in venture financing to date.
Mr. Chan holds a B.S. in Biomedical Engineering from Johns Hopkins University and an M.B.A. from the Wharton School at the University of Pennsylvania.
Board of Senior Advisors
Robert F. Higgins – Chairman
Mr. Higgins is a founding General Partner at Highland Capital Partners and has more than twenty-five years of experience in venture capital, having helped Highland raise nearly $3.5 billion since 1988. He has served as a director of many public and private companies. He is a former director of the National Venture Capital Association and President of the New England Venture Capital Association. In addition, Mr. Higgins has been recognized by the prestigious Forbes Midas List and AlwaysOn Venture Capital 100 as one of the top venture capitalists in the industry. In 2011, he was named a member of the American Academy of Arts and Sciences.
Mr. Higgins has been a faculty member at the Harvard Business School since 2001 and teaches at the Kennedy School of Government. He received the 2008 HBS Healthcare Alumni Achievement Award. Prior to entering venture capital, he spent four years as the Executive Director of the John A. Hartford Foundation. He also was the Chief Executive of the Clark Foundation and the Burden Foundation.
Mr. Higgins is a former Assistant to the US Secretary of Commerce and an Assistant to the head of the international division of the US Treasury. Additionally, he is a Member of the Council on Foreign Relations and a member of the Massachusetts General Hospital Research Advisory Council. He has an A.B. from Harvard College and an M.B.A. from Harvard Business School.